The Federal Government has published the following proposed amending regulations in Part 1 of the Canada Gazette:
- Regulations Amending the Food and Drug Regulations (Exports and Transhipments of Drugs): The amendments would extend drug establishment licensing and Good Manufacturing Practices (GMP) requirements to persons conducting licensable activities with drugs solely for export. Additionally, the proposed amendments would also clarify that drugs in transhipment through Canada must be in bond. Consultation on the proposed amendments is open until August 26, 2021.
- Regulations Amending the Natural Health Products Regulations: As per Health Canada’s news release, the proposed amendments seek to make natural health product labels more clear, legible, and easier to understand. Consultation on the proposed amendments is open until September 4, 2021.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Medical Devices updates: Phase II consultation on Medical Devices Regulations amendments, medical device licences guidance and IMDRF table of contents guidance
On November 17, 2025, Health Canada proposed Phase II amendments to the Medical Devices Regulations (MDR). The first phase of amendments came into force on December 14, 2024 and relate to recalls, mod...Read More -
Proposal for modernizing clinical trial framework aims to improve access to new and innovative therapies in Canada
On December 20, 2025, Health Canada launched a consultation on modernizing the framework for clinical trials involving drugs for human use, including pharmaceuticals, biologics, radiopharmaceuticals, ...Read More -
Health Canada consultation on two draft guidance documents on terms and conditions for human and veterinary drugs and drug submissions based on promising evidence of clinical efficacy
As previously reported, in December 2024, Health Canada published its agile licensing amendments to the Food and Drug Regulations.Read More
